Results 111 to 120 of about 12,211 (152)

Managing reactivation of multiple sclerosis during treatment with natalizumab. [PDF]

Mult Scler
Lizak N, Sharmin S, Horáková D, Havrdova EK, Eichau S, van der Walt A, Butzkueven H, Lechner-Scott J, Buzzard K, Skibina O, Gerlach O, Prat A, Girard M, Duquette P, Alroughani R, Patti F, Grand'Maison F, Sá MJ, Aguera-Morales E, Hodgkinson S, Grammond P, Kuhle J, Yamout B, Khoury SJ, Ozakbas S, Csepany T, John N, Laureys G, Terzi M, Amato MP, Boz C, Al-Asmi A, Cartechini E, Gouider R, Mrabet S, Roos I, Kalincik T.   +36 more
europepmc   +1 more source

CD56^brightNK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B-cell-depleting therapy. [PDF]

Clin Transl Immunology
Perkins GB, Hope CM, Chai CS, Tunbridge MJ, Sterling S, Webb K, Yap J, Yeow AEL, Masavuli MG, Scaffidi J, Zuiani JD, Akerman A, Aggarwal A, Milogiannakis V, Roberts MB, Hurtado PR, Turville S, Grubor-Bauk B, Barry SC, Ravindran J, Coates PT, Hissaria P.   +21 more
europepmc   +1 more source

Clinical relevance and predictors of anti-natalizumab antibodies in multiple sclerosis: A real-world retrospective cohort study. [PDF]

Mult Scler J Exp Transl Clin
Levy M, Beigneux Y, Roux T, Mossad M, Ricigliano V, Senant M, Papeix C, Stankoff B, Louapre C, Maillart E, Lazzarotto A.   +10 more
europepmc   +1 more source

Combining Pembrolizumab and Ofatumumab in Triple-Negative Breast Cancer and Multiple Sclerosis: A Case Report. [PDF]

Surg Case Rep
Iriyama H, Iwase M, Takano Y, Takeuchi D, Ichikawa T, Ohata R, Ozaki Y, Yamamoto M, Inaguma G, Torii N, Toyoda C, Kawabe K, Kikumori T, Masuda N.   +13 more
europepmc   +1 more source

Refined single-cell profiling captures a CCR5^high CD4⁺ cytotoxic T-cell precursor in multiple sclerosis. [PDF]

EBioMedicine
van Puijfelik F, Rip J, van Hasselt Y, Wierenga-Wolf AF, Shyfrin S, Pelser AC, Melief MJ, Klein Kranenbarg RAM, Bindels EM, van de Werken HJG, van Ansenwoude CMJ, de Vries HE, Dik WA, de Beukelaar J, Smets I, Wokke BH, Smolders J, van Luijn MM.   +17 more
europepmc   +1 more source

Use of multiple sclerosis drugs among pregnant individuals with live-birth deliveries in the FDA's Sentinel Distributed Database. [PDF]

BMC Pregnancy Childbirth
Stojanovic D, Taylor L, Shinde M, Haug N, Mohamoud M, Sahin L, Carruth A, Hawrusik R, Lyons JG.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Natalizumab

Neurology, 2009
Since it first came to trial, natalizumab (Tysabri) has kept the multiple sclerosis (MS) world in a constant state of flux. Shortly after its initial launch, the appearance of three cases of progressive multifocal leukoencephalopathy (PML), a devastating infection of the CNS caused by the JC virus, resulted in the drug’s withdrawal from the market ...
Nicoline, Schiess, Peter A, Calabresi
  +6 more sources

Natalizumab update

American Journal of Health-System Pharmacy, 2007
The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of natalizumab are reviewed.Natalizumab, the first commercially available selective adhesion-molecule inhibitor, is approved as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis (MS ...
openaire   +2 more sources

Natalizumab

Reactions Weekly, 2015
  +9 more sources